AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS Gene Therapy
Reports from University of Toronto, Department of Pharmaceutical Sciences advance knowledge in HIV/AIDS gene therapy
November 3rd, 2008
New investigation results, 'Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line,' are detailed in a study published in Pharmaceutical Research. "Protease inhibitors (PIs) exhibit low brain permeability. As a result, unchallenged HIV viral replication can lead to HIV-encephalitis and antiretroviral drug resistance," researchers in Canada report.
"The objective of this study was to develop and evaluate a lipid nanoparticle system for enhanced brain delivery of the potent and frequently used HIV PI, atazanavir, using a well characterized human brain microvessel endothelial cell line...
Source: AIDS Weekly (2008-11-03)
|
